A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors

Cancer Research

Volumn 76, Issue 13, 2016, Pages 3942-3953

  Moores, Sheri L ^a   Chiu, Mark L ^a   Bushey, Barbara S ^a   Chevalier, Kristen ^a   Luistro, Leopoldo ^a   Dorn, Keri ^a   Brezski, Randall J ^a   Haytko, Peter ^a   Kelly, Thomas ^a   Wu, Sheng Jiun ^a   Martin, Pauline L ^a   Neijssen, Joost ^b   Parren, Paul W H I ^b,c   Schuurman, Janine ^b   Attar, Ricardo M ^a   Laquerre, Sylvie ^a   Lorenzi, Matthew V ^a   Anderson, G Mark ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b GENMAB   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; JNJ 61186372; MITOGEN ACTIVATED PROTEIN KINASE; OSIMERTINIB; ROCILETINIB; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; MACACA FASCICULARIS; MOLECULAR INTERACTION; MOUSE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SKIN TOXICITY; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84977497581     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2833     Document Type: Article

References (32)

1. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFRmutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
2. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22: 3238-47.
3. Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009;15:651-8.
4. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
5. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
6. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
7. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
8. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011;6:2011-7.
9. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
10. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
11. Jiang SX, Yamashita K, Yamamoto M, Piao CJ, Umezawa A, Saegusa M, et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. Int J Cancer 2008;123:2480-6.
12. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 2013;110:5145-50.
13. Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014;9:2450-63.
14. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6:1161-73.
15. Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, Peipp M, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A 2008;105:6109-14.
16. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11.
17. Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, et al. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012;14: 1023-31.
18. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013;110:E2987-96.
19. Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy E, Sanders R, et al. Impact of cell-surface antigen expression on target engagement and function of an EGFR x c-Met bispecific antibody. J Biol Chem 2015;290: 24689-704.
20. Cartron G, Dacheu L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene. Blood 2002; 99:754-8.
21. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin Gmolecules can adversely impact functionality. Mol Immunol 2007;44:1524-34.
22. Brezski RJ, Luongo JL, Petrone D, Ryan MH, Zhong D, Tam SH, et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol 2008;181:3183-92.
23. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996; 74:505-13.
24. Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2014;65:114-26.
25. U.S. Food and Drug Administration. FDA approval information. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/bla/2004/125084-ERBITUX-PHARMR-P3.PDF; http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/125147s0000-PharmR.pdf.
26. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7.
27. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AXD9291 in nonsmall cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560-4.
28. Planchard D, Loriot Y, André F, Gobert A, Auger N, Lacroix L, et al. EGFR independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 2015;26:2073-8.
29. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcomea major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10.
30. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, et al. Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015;7:713-22.
31. Zheng S, Moores S, Jarantow S, Pardinas J, Chiu M, Zhou H, et al. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs 2016; 8:551-61.
32. Janjigian YY, Smit EF, Groen HJ, Horn L, Gettinger S, Camidge DR, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitorresistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014;4:1036-45.